309 related articles for article (PubMed ID: 35489038)
41. KDM6A epigenetically regulates subtype plasticity in small cell lung cancer.
Duplaquet L; Li Y; Booker MA; Xie Y; Olsen SN; Patel RA; Hong D; Hatton C; Denize T; Walton E; Laimon YN; Li R; Jiang Y; Bronson RT; Southard J; Li S; Signoretti S; Qiu X; Cejas P; Armstrong SA; Long HW; Tolstorukov MY; Haffner MC; Oser MG
Nat Cell Biol; 2023 Sep; 25(9):1346-1358. PubMed ID: 37591951
[TBL] [Abstract][Full Text] [Related]
42. SCLC-CellMiner: A Resource for Small Cell Lung Cancer Cell Line Genomics and Pharmacology Based on Genomic Signatures.
Tlemsani C; Pongor L; Elloumi F; Girard L; Huffman KE; Roper N; Varma S; Luna A; Rajapakse VN; Sebastian R; Kohn KW; Krushkal J; Aladjem MI; Teicher BA; Meltzer PS; Reinhold WC; Minna JD; Thomas A; Pommier Y
Cell Rep; 2020 Oct; 33(3):108296. PubMed ID: 33086069
[TBL] [Abstract][Full Text] [Related]
43. An integrative transcriptome analysis reveals a functional role for thyroid transcription factor-1 in small cell lung cancer.
Horie M; Miyashita N; Mattsson JSM; Mikami Y; Sandelin M; Brunnström H; Micke P; Nagase T; Saito A
J Pathol; 2018 Oct; 246(2):154-165. PubMed ID: 29876935
[TBL] [Abstract][Full Text] [Related]
44. Significance of achaete-scute complex homologue 1 (ASCL1) in pulmonary neuroendocrine carcinomas; RNA sequence analyses using small cell lung cancer cells and Ascl1-induced pulmonary neuroendocrine carcinoma cells.
Kudoh S; Tenjin Y; Kameyama H; Ichimura T; Yamada T; Matsuo A; Kudo N; Sato Y; Ito T
Histochem Cell Biol; 2020 Jun; 153(6):443-456. PubMed ID: 32170367
[TBL] [Abstract][Full Text] [Related]
45. Protein Expression of immune checkpoints STING and MHCII in small cell lung cancer.
Dora D; Rivard C; Yu H; Pickard SL; Laszlo V; Harko T; Megyesfalvi Z; Gerdan C; Dinya E; Hoetzenecker K; Hirsch FR; Lohinai Z; Dome B
Cancer Immunol Immunother; 2023 Mar; 72(3):561-578. PubMed ID: 35978199
[TBL] [Abstract][Full Text] [Related]
46. ASCL1 represses a SOX9
Olsen RR; Ireland AS; Kastner DW; Groves SM; Spainhower KB; Pozo K; Kelenis DP; Whitney CP; Guthrie MR; Wait SJ; Soltero D; Witt BL; Quaranta V; Johnson JE; Oliver TG
Genes Dev; 2021 Jun; 35(11-12):847-869. PubMed ID: 34016693
[TBL] [Abstract][Full Text] [Related]
47. Sensitivity of Small Cell Lung Cancer to BET Inhibition Is Mediated by Regulation of ASCL1 Gene Expression.
Lenhart R; Kirov S; Desilva H; Cao J; Lei M; Johnston K; Peterson R; Schweizer L; Purandare A; Ross-Macdonald P; Fairchild C; Wong T; Wee S
Mol Cancer Ther; 2015 Oct; 14(10):2167-74. PubMed ID: 26253517
[TBL] [Abstract][Full Text] [Related]
48. [Heterogeneity of small cell lung cancer: biological and clinicopathological implications].
Megyesfalvi Z; Bárány N; Valkó Z; Bugyik E; Paku S; Berta J; Lantos A; Fillinger J; Moldvay J; Bogos K; Rezeli M; Gálffy G; Lang C; Lohinai Z; Hécz R; Lovas T; Rényi-Vámos F; László V; Döme B
Magy Onkol; 2020 Sep; 64(3):243-255. PubMed ID: 34608895
[TBL] [Abstract][Full Text] [Related]
49. Molecular subtypes of small cell lung cancer: a synthesis of human and mouse model data.
Rudin CM; Poirier JT; Byers LA; Dive C; Dowlati A; George J; Heymach JV; Johnson JE; Lehman JM; MacPherson D; Massion PP; Minna JD; Oliver TG; Quaranta V; Sage J; Thomas RK; Vakoc CR; Gazdar AF
Nat Rev Cancer; 2019 May; 19(5):289-297. PubMed ID: 30926931
[TBL] [Abstract][Full Text] [Related]
50. Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilities.
Gay CM; Stewart CA; Park EM; Diao L; Groves SM; Heeke S; Nabet BY; Fujimoto J; Solis LM; Lu W; Xi Y; Cardnell RJ; Wang Q; Fabbri G; Cargill KR; Vokes NI; Ramkumar K; Zhang B; Della Corte CM; Robson P; Swisher SG; Roth JA; Glisson BS; Shames DS; Wistuba II; Wang J; Quaranta V; Minna J; Heymach JV; Byers LA
Cancer Cell; 2021 Mar; 39(3):346-360.e7. PubMed ID: 33482121
[TBL] [Abstract][Full Text] [Related]
51. POU2F3: A Sensitive and Specific Diagnostic Marker for Neuroendocrine-low/negative Small Cell Lung Cancer.
Wang Y; Jin Y; Shen X; Zheng Q; Xue Q; Chen L; Lin Y; Li Y
Am J Surg Pathol; 2023 Sep; 47(9):1059-1066. PubMed ID: 37357936
[TBL] [Abstract][Full Text] [Related]
52. Killing SCLC: insights into how to target a shapeshifting tumor.
Sutherland KD; Ireland AS; Oliver TG
Genes Dev; 2022 Mar; 36(5-6):241-258. PubMed ID: 35318269
[TBL] [Abstract][Full Text] [Related]
53. YAP1 expression is associated with survival and immunosuppression in small cell lung cancer.
Chen P; Sun C; Wang H; Zhao W; Wu Y; Guo H; Zhou C; He Y
Cell Death Dis; 2023 Sep; 14(9):636. PubMed ID: 37752152
[TBL] [Abstract][Full Text] [Related]
54. Comparative analysis of TTF-1 binding DNA regions in small-cell lung cancer and non-small-cell lung cancer.
Hokari S; Tamura Y; Kaneda A; Katsura A; Morikawa M; Murai F; Ehata S; Tsutsumi S; Ishikawa Y; Aburatani H; Kikuchi T; Miyazono K; Koinuma D
Mol Oncol; 2020 Feb; 14(2):277-293. PubMed ID: 31782890
[TBL] [Abstract][Full Text] [Related]
55. Identification of Lineage-specific Transcriptional Factor-defined Molecular Subtypes in Small Cell Bladder Cancer.
Feng M; Matoso A; Epstein G; Fong M; Park YH; Gabrielson A; Patel S; Czerniak B; Compérat E; Hoffman-Censits J; Kates M; Kim S; McConkey D; Choi W
Eur Urol; 2024 Jun; 85(6):523-526. PubMed ID: 37380560
[TBL] [Abstract][Full Text] [Related]
56. ASCL1 is a lineage oncogene providing therapeutic targets for high-grade neuroendocrine lung cancers.
Augustyn A; Borromeo M; Wang T; Fujimoto J; Shao C; Dospoy PD; Lee V; Tan C; Sullivan JP; Larsen JE; Girard L; Behrens C; Wistuba II; Xie Y; Cobb MH; Gazdar AF; Johnson JE; Minna JD
Proc Natl Acad Sci U S A; 2014 Oct; 111(41):14788-93. PubMed ID: 25267614
[TBL] [Abstract][Full Text] [Related]
57. Tumor-derived Vimentin as a novel biomarker for distinct subtypes predicting adjuvant chemotherapy resistance and T-cell-inflamed phenotype in small cell lung cancer.
Deng C; Wang Y; Fu F; Li D; Zheng Q; Jin Y; Li Y; Chen H; Zhang Y
MedComm (2020); 2023 Oct; 4(5):e370. PubMed ID: 37789961
[TBL] [Abstract][Full Text] [Related]
58. System analysis identifies distinct and common functional networks governed by transcription factor ASCL1, in glioma and small cell lung cancer.
Donakonda S; Sinha S; Dighe SN; Rao MRS
Mol Biosyst; 2017 Jul; 13(8):1481-1494. PubMed ID: 28742165
[TBL] [Abstract][Full Text] [Related]
59. Standard therapy-resistant small cell lung cancer showing dynamic transition of neuroendocrine fate during the cancer trajectory: A case report.
Ito F; Sato T; Emoto K; Kaizuka N; Yagi K; Watanabe R; Hashiguchi MH; Ninomiya H; Ikematsu Y; Tanaka K; Domoto H; Shiomi T
Mol Clin Oncol; 2021 Dec; 15(6):261. PubMed ID: 34790350
[TBL] [Abstract][Full Text] [Related]
60. Potential subtype-specific therapeutic approaches in small cell lung cancer.
Horvath L; Lang C; Boettiger K; Aigner C; Dome B; Megyesfalvi Z
Curr Opin Oncol; 2024 Jan; 36(1):51-56. PubMed ID: 37865844
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
